Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression

Open access

Abstract

Inhibition of JAK1 or JAK2 in human tumor cells was previously shown to increase susceptibility of these cells to NK cell lysis. In the present study, we examined the cellular mechanisms that mediate this effect in hematopoietic tumor cell lines and primary tumor cells. Incubation of tumor cells with supernatant from activated NK cells or interferon-gamma (IFNγ)-induced activation of pSTAT1 and increased expression of PD-L1 without altering expression of other activating or inhibitory NK cell ligands. These functional effects were blocked by chemical JAK inhibition or shRNAs targeting JAK1, JAK2 or STAT1. Inhibition of IFNγ signaling also prevented the upregulation of PD-L1 and blocking PD-L1 resulted in increased tumor lysis by NK cells. These results show that NK cell activation and secretion of IFNγ results in activation of JAK1, JAK2 and STAT1 in tumor cells, resulting in rapid up-regulation of PD-L1 expression. Increased expression of PD-L1 results in increased resistance to NK cell lysis. Blockade of JAK pathway activation prevents increased PD-L1 expression resulting in increased susceptibility of tumor cells to NK cell activity. These observations suggest that JAK pathway inhibitors as well as PD-1 and PD-L1 antibodies may work synergistically with other immune therapies by preventing IFN-induced inhibition of NK cell-mediated tumor cell lysis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2015.1008824

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Baseline phosphorylation of STAT proteins, AKT and ERK in hematopoietic tumor cell lines and primary tumor cells. Representative examples of hematopoietic tumor cell lines or primary tumor cells analyzed for expression of several pSTAT proteins, pAKT and pERK at their basal level and after pre-treatment with a JAK inhibitor. Bar graphs indicate mean fluorescence intensity (MFI) expression determined by flow cytometry.
Figure 1. Baseline phosphorylation of STAT proteins, AKT and ERK in hematopoietic tumor cell lines and primary tumor cells. Representative examples of hematopoietic tumor cell lines or primary tumor cells analyzed for expression of several pSTAT proteins, pAKT and pERK at their basal level and after pre-treatment with a JAK inhibitor. Bar graphs indicate mean fluorescence intensity (MFI) expression determined by flow cytometry.CC BY-NC · PubMed Central
Figure 2. STAT1(pY701)activation after treatment with activated NK supernatant. Different hematopoietic tumor lines and primary tumor cells were treated with activated NK supernatant from primary NK cells stimulated with tumor cells and subsequently analyzed for expression of pSTATs, pAKT and pERK by flow cytometry. Levels of phosphorylation were measured before and after treatment with NK supernatant in cells pre-treated with 40 nm JAK inhibitor1. Bar graphs indicate mean fluorescence intensity (MFI) expression determined by flow cytometry.
Figure 2. STAT1(pY701)activation after treatment with activated NK supernatant. Different hematopoietic tumor lines and primary tumor cells were treated with activated NK supernatant from primary NK cells stimulated with tumor cells and subsequently analyzed for expression of pSTATs, pAKT and pERK by flow cytometry. Levels of phosphorylation were measured before and after treatment with NK supernatant in cells pre-treated with 40 nm JAK inhibitor1. Bar graphs indicate mean fluorescence intensity (MFI) expression determined by flow cytometry.CC BY-NC · PubMed Central
Figure 3. Effects of STAT1 knockdown in hematopoietic tumor cell lines. K562, KM12BM and IM-9 were stably transduced with two independent shRNAs targeting STAT1 and two irrelevant shRNAs as control. (A) The level of total STAT1 expression was evaluated by flow cytometry and (B) western blot analysis. Controls and STAT1-KO cell lines were incubated with primary purified NK effector cells pre-stimulated with 100 Units/mL IL-2 at 1:1 E/T ratio as described in Methods. (C) Levels of IFNγ secretion in culture supernatants, (D) percent NK cells expressing CD107a/b and (E) Killing of STAT1-KO and control cell lines mediated by fresh purified NK. Bars represent the specific lysis of target cells (mean ± SEM) of four different experiments (∗p < 0.05, ∗∗p < 0.01 compared to the isotype control with the highest reactivity).
Figure 3. Effects of STAT1 knockdown in hematopoietic tumor cell lines. K562, KM12BM and IM-9 were stably transduced with two independent shRNAs targeting STAT1 and two irrelevant shRNAs as control. (A) The level of total STAT1 expression was evaluated by flow cytometry and (B) western blot analysis. Controls and STAT1-KO cell lines were incubated with primary purified NK effector cells pre-stimulated with 100 Units/mL IL-2 at 1:1 E/T ratio as described in Methods. (C) Levels of IFNγ secretion in culture supernatants, (D) percent NK cells expressing CD107a/b and (E) Killing of STAT1-KO and control cell lines mediated by fresh purified NK. Bars represent the specific lysis of target cells (mean ± SEM) of four different experiments (∗p < 0.05, ∗∗p < 0.01 compared to the isotype control with the highest reactivity).CC BY-NC · PubMed Central
Figure 4. Effects of IFNγ-blocking antibody on tumor cell susceptibility to NK lysis. (A) Five hematopoietic tumor cell lines and (B) primary tumor cells were incubated with primary purified NK cells at 1:1 E/T ratio in the presence of an anti-IFNγ-blocking antibody (D9D10) or an isotype control. Bars represent the specific lysis of target cells (mean ± SEM) of four different experiments (∗p < 0.05, ∗∗p < 0.01 compared to the isotype control with the highest reactivity).
Figure 4. Effects of IFNγ-blocking antibody on tumor cell susceptibility to NK lysis. (A) Five hematopoietic tumor cell lines and (B) primary tumor cells were incubated with primary purified NK cells at 1:1 E/T ratio in the presence of an anti-IFNγ-blocking antibody (D9D10) or an isotype control. Bars represent the specific lysis of target cells (mean ± SEM) of four different experiments (∗p < 0.05, ∗∗p < 0.01 compared to the isotype control with the highest reactivity).CC BY-NC · PubMed Central
Figure 5. Tumor cell expression of PD-L1 and PD-L2 after incubation with activated NK supernatant or IFNγ. (A) Expression of PD-L1 in a representative example of AML cells treated with NK supernatant (left panel) or IFNγ (right panel) and with the addition of JAK inhibitor. (B) Expression of PD-L1 in hematopoietic tumor cell lines and primary tumor cells and expression of PD-L2 in U937 and primary AML cells. Surface antigen expression (MFI) is compared in cells incubated with medium alone, NK supernatant or IFNγ with or without JAK inhibitor. (C) Expression of PD-L1 in K562 or K562-STAT1-KO cells treated with NK supernatant (left panel) or IFNγ (right panel). (D) Expression of PD-L1 in 3 STAT1-KO or sh-CTRL cell lines. PD-L1 expression (MFI) is compared in cells incubated with medium alone, NK-supernatant or IFNγ.
Figure 5. Tumor cell expression of PD-L1 and PD-L2 after incubation with activated NK supernatant or IFNγ. (A) Expression of PD-L1 in a representative example of AML cells treated with NK supernatant (left panel) or IFNγ (right panel) and with the addition of JAK inhibitor. (B) Expression of PD-L1 in hematopoietic tumor cell lines and primary tumor cells and expression of PD-L2 in U937 and primary AML cells. Surface antigen expression (MFI) is compared in cells incubated with medium alone, NK supernatant or IFNγ with or without JAK inhibitor. (C) Expression of PD-L1 in K562 or K562-STAT1-KO cells treated with NK supernatant (left panel) or IFNγ (right panel). (D) Expression of PD-L1 in 3 STAT1-KO or sh-CTRL cell lines. PD-L1 expression (MFI) is compared in cells incubated with medium alone, NK-supernatant or IFNγ.CC BY-NC · PubMed Central
Figure 6. Effect of blocking PD-L1 on NK cell lysis of tumor cells. Tumor cell lines and primary tumor cells were incubated with (A) primary purified NK cells or (B) NK-92 at 1:1 E/T ratio with or without 10 μg/mL PDL1 antibody, JAK inhibitor or JAK inhibitor + PD-L1 antibody. The percentage of AnnexinV/7AAD positive cells was calculated for gated target cells (NKG2A or CD56 negative). Bars represent specific percent target cell killing (mean ± SEM) obtained in three separate experiments (∗p < 0.05, ∗∗p < 0.01 compared to target cells without PD-L1 antibody or JAK inhibitor treatment).
Figure 6. Effect of blocking PD-L1 on NK cell lysis of tumor cells. Tumor cell lines and primary tumor cells were incubated with (A) primary purified NK cells or (B) NK-92 at 1:1 E/T ratio with or without 10 μg/mL PDL1 antibody, JAK inhibitor or JAK inhibitor + PD-L1 antibody. The percentage of AnnexinV/7AAD positive cells was calculated for gated target cells (NKG2A or CD56 negative). Bars represent specific percent target cell killing (mean ± SEM) obtained in three separate experiments (∗p < 0.05, ∗∗p < 0.01 compared to target cells without PD-L1 antibody or JAK inhibitor treatment).CC BY-NC · PubMed Central
Figure 7. Hypothetical mechanism forIFNγ pathway modulation of tumor susceptibility to NK cells. (A) Upon engagement with target cells, NK cells secrete IFNγ, which in turn activates JAK1, JAK2 and STAT1 in tumor cells. This signal upregulates expression of PD-L1 on tumor cells resulting in increased resistance to NK cell killing. (B) Inhibition of JAK1 or JAK2 activation or IFNγ blocks upregulation of PD-L1 resulting in increased susceptibility of tumor cells to NK cell lysis.
Figure 7. Hypothetical mechanism forIFNγ pathway modulation of tumor susceptibility to NK cells. (A) Upon engagement with target cells, NK cells secrete IFNγ, which in turn activates JAK1, JAK2 and STAT1 in tumor cells. This signal upregulates expression of PD-L1 on tumor cells resulting in increased resistance to NK cell killing. (B) Inhibition of JAK1 or JAK2 activation or IFNγ blocks upregulation of PD-L1 resulting in increased susceptibility of tumor cells to NK cell lysis.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Research works printed but not linked: 3

  1. Creagan ET, 1987, Cancer TreatReports, 71, 843
  2. Gong JH, 1994, Leukemia, 8, 652
  3. Robertson MJ, 1996, ExpHematol, 24, 406

Cited by

See all 356

Metadata

Authors
Bellucci, R., Martin, A., Bommarito, D., Wang, K., Hansen, S. H., Freeman, G. J., & Ritz, J.
Affiliations
  • Brigham and Women's Hospital (US)
  • Dana-Farber Cancer Institute (US)
Corresponding author
  • Bellucci, Roberto
  • Ritz, Jerome
Venue
OncoImmunology
Published
2015-03-02
Volume
4
Issue
6
Pages
e1008824
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W1510735640
Cited by
307
References
51
Citations by year
2026: 10 · 2025: 23 · 2024: 38 · 2023: 30 · 2022: 20 · 2021: 35 · 2020: 36 · 2019: 29 · 2018: 33 · 2017: 28 · 2016: 22 · 2015: 3
FWCI
14.10
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • OncoImmunology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
Funders
National Cancer Institute (P01CA142106, P50CA101942, R01CA183560, P01CA066996)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
Keywords
interferon-gamma, JAK1, JAK2, STAT1, PD-L1, NK cell-mediated lysis, NK cell resistance, tumor cell susceptibility, JAK inhibition, hematopoietic tumors, immune checkpoint blockade, PD-1, combination immunotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. https://app.cochat.ai/papers/10.1080/2162402x.2015.1008824
The paper
Bellucci, R., Martin, A., Bommarito, D., Wang, K., Hansen, S. H., Freeman, G. J., & Ritz, J. (2015). Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. OncoImmunology. https://doi.org/10.1080/2162402x.2015.1008824

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.